Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Up 97.4% in April

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the recipient of a significant growth in short interest during the month of April. As of April 30th, there was short interest totaling 46,010 shares, a growth of 97.4% from the April 15th total of 23,312 shares. Based on an average daily trading volume, of 31,445 shares, the short-interest ratio is currently 1.5 days. Approximately 0.9% of the company’s stock are short sold.

Institutional Investors Weigh In On Neuphoria Therapeutics

A number of large investors have recently added to or reduced their stakes in NEUP. AdvisorShares Investments LLC boosted its position in Neuphoria Therapeutics by 129.1% during the fourth quarter. AdvisorShares Investments LLC now owns 134,194 shares of the company’s stock worth $521,000 after purchasing an additional 75,631 shares during the period. Ikarian Capital LLC bought a new stake in Neuphoria Therapeutics during the fourth quarter worth approximately $184,000. ADAR1 Capital Management LLC bought a new stake in Neuphoria Therapeutics during the fourth quarter worth approximately $116,000. Diadema Partners LP boosted its position in Neuphoria Therapeutics by 133.1% during the fourth quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock worth $194,000 after purchasing an additional 28,548 shares during the period. Finally, FNY Investment Advisers LLC bought a new stake in Neuphoria Therapeutics during the fourth quarter worth approximately $102,000. Institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Trading Down 7.1%

Neuphoria Therapeutics stock traded down $0.36 during trading hours on Friday, reaching $4.73. 79,662 shares of the company were exchanged, compared to its average volume of 28,729. The firm has a market cap of $25.49 million, a price-to-earnings ratio of -0.43 and a beta of 0.72. The stock has a 50-day moving average of $4.72 and a 200 day moving average of $4.38. Neuphoria Therapeutics has a 12 month low of $3.64 and a 12 month high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its earnings results on Tuesday, May 19th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.47. As a group, research analysts forecast that Neuphoria Therapeutics will post -4.07 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. HC Wainwright downgraded Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday. Zacks Research upgraded Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Neuphoria Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $21.00.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.